- Previous Close
236.23 - Open
237.02 - Bid 234.59 x 1400
- Ask 234.82 x 900
- Day's Range
234.01 - 237.26 - 52 Week Range
167.42 - 261.73 - Volume
340,111 - Avg. Volume
1,202,736 - Market Cap (intraday)
42.709B - Beta (5Y Monthly) 1.50
- PE Ratio (TTM)
30.43 - EPS (TTM)
7.70 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
274.56
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
www.iqvia.com88,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IQV
View More
Performance Overview: IQV
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IQV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IQV
View MoreValuation Measures
Market Cap
43.06B
Enterprise Value
54.84B
Trailing P/E
30.68
Forward P/E
18.76
PEG Ratio (5yr expected)
1.16
Price/Sales (ttm)
2.88
Price/Book (mrq)
6.41
Enterprise Value/Revenue
3.62
Enterprise Value/EBITDA
16.44
Financial Highlights
Profitability and Income Statement
Profit Margin
9.39%
Return on Assets (ttm)
5.03%
Return on Equity (ttm)
22.84%
Revenue (ttm)
15.16B
Net Income Avi to Common (ttm)
1.42B
Diluted EPS (ttm)
7.70
Balance Sheet and Cash Flow
Total Cash (mrq)
1.68B
Total Debt/Equity (mrq)
202.46%
Levered Free Cash Flow (ttm)
1.64B
Research Analysis: IQV
View MoreCompany Insights: IQV
IQV does not have Company Insights
Research Reports: IQV
View MoreIQVIA Earnings: Healthy Results Drive Long-Term Growth; Raising Fair Value Estimate to $268
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
RatingPrice TargetIQVIA Earnings: Healthy Results Drive Long-Term Growth; Raising Fair Value Estimate to $268
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
RatingPrice TargetIQVIA Earnings: Healthy Results Drive Long-Term Growth; Raising Fair Value Estimate to $268
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
RatingPrice TargetRaising EPS estimates for 2024 and 2025
IQVIA Holdings is the world's largest provider of biopharmaceutical development services and commercial outsourcing services. The company is the result of the 2016 merger of Quintiles Transnational, a contract research organization, and IMS Health, a healthcare data and analytics provider. IQVIA is headquartered in Research Triangle Park, North Carolina. IQVIA provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. IQVIA provides intelligent connections across all aspects of healthcare through its analytics, technology, big data resources, and extensive domain expertise. Its Connected Intelligence delivers actionable insights to enable customers to accelerate the clinical development and commercialization of new therapies. The company has about 86,000 employees. IQVIA has one of the largest collections of healthcare information in the world, which includes more than 1.2 billion comprehensive, longitudinal, non-identified patient records spanning sales and prescription data, medical claims, electronic medical records, genomics, and social media.
RatingPrice Target